CTIS2023-509863-26-00招募中1 期
Stop of proton-pump inhibitor treatment in patients with liver cirrhosis – a doubleblind, placebo-controlled trial (STOPPIT) - STOPPIT
niversity Medical Center Hamburg-Eppendorf0 个研究点目标入组 476 人开始时间: 2024年5月6日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 476
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Male or female adult (18 years) patient., Provided written informed consent., Liver cirrhosis (diagnosed either histologically or by a combination of clinical, laboratory and/or radiological signs)., Hospitalized or recently hospitalized (0 to 42 days before baseline) with complicated liver cirrhosis., PPI treatment for at least 28 days prior to screening, PPI treatment with a single standard dose/day or less for a minimum of 7 days prior to screening., Females/Males who agree to comply with the applicable contraceptive requirements of the protocol., Non-pregnant, non-lactating females., Ability to understand the patient information and to personally sign and date the informed consent to participate in the study, before completing any study related procedures., The patient is co-operative and available for the entire study.
排除标准
- •Severe esophageal reflux disease (LA grade C or D) diagnosed by esophago-gastro-duodenoscopy (EGD) < 2 months prior to screening without PPI treatment for at least 8 weeks prior to screening., Positive urine pregnancy test at screening or positive serum pregnancy test before the first treatment or is breast feeding., Patient is not willing to use adequate contraceptive precautions during the study or for up to 5 days after the last scheduled dose of IMP., Peptic ulcers diagnosed by EGD < 28 days prior to screening., Endoscopic therapy for varices < 14 days prior to screening., Life-expectancy < 1 year (at the discretion of the investigator) due to extrahepatic malignancies, metastasized hepatocellular carcinoma (HCC), or other severe extrahepatic-diseases. Importantly, HCC without extrahepatic metastases or a reduced life-expectancy < 1 year due to liver cirrhosis are not regarded as exclusion criteria., Regular intake of non-steroidal anti-inflammatory drugs on a daily basis with the exemption of acetylsalicylic acid in a dosage of up to 100mg/day., Patients with one or more of the following measurements at the time of screening or documented during 48 hours before screening: a. Body temperature > 38.5°C, or b. systolic blood pressure < 90 mmHg and tachycardia > 100 beats per minute, or c. ongoing catecholamine treatment higher than low dose norepinephrine ( 0.1 µg/kg/minute) (NB: terlipressin treatment for possible hepatorenal syndrome is not regarded as an exclusion criterion), or d. respiratory rate 22/minute., Hypersensitivity or intolerance to esomeprazole, substituted benzimidazoles or other excipients of the investigational medicinal product (IMP; Nexium mups or Placebo)., Ongoing therapy with nelfinavir., Participating in a clinical trial or use of an IMP within 30 days or five times the half-life of the IMP (whichever is longer) prior to receive the first dose within this study.
研究者
相似试验
招募中
3 期
Stop of proton-pump inhibitor treatment in patients with liver cirrhosis - a double-blind, placebo-controlled trialK74K65R18K72K72.79R17A49K76.7Fibrosis and cirrhosis of liverAscitesHepatic failure, not elsewhere classifiedHyperbilirubinaemia, with or without jaundice, not elsewhere classifiedBacterial infection of unspecified sitePeritonitisHepatorenal syndromeDRKS00021290niversitätsklinikum Hamburg-Eppendorf476
招募中
4 期
Stop of proton-pump inhibitor treatment in patients with liver cirrhosis – a doubleblind, placebo-controlled trial (STOPPIT)2023-509863-26-00University Medical Center Hamburg-Eppendorf476
进行中（未招募）
1 期
Withdrawal of pharmacological treatment in patients responding to cardiac resynchronization therapy: Open and randomized studyHeart failureEUCTR2021-001327-41-ESFundación para la formación e investigación sanitarias de la Región de Murcia60
招募中
1 期
Withdrawal of Pharmacological Treatment in Patients Responding to Cardiac Resynchronization Therapy: (REMOVE)MedDRA version: 20.0Level: LLTClassification code: 10019279Term: Heart failure Class: 10007541Heart FailureCTIS2023-504946-70-00Fundacion Para La Formacion E Investigacion Sanitaria De La Region De Murcia60
已完成
不适用
The influence of proton pump inhibitor therapy on the clinical course of COVID-19SARS-CoV2J12.8J80.0Other viral pneumoniaDRKS00021523niversitätsklinikum Freiburg, Klinik für Innere Medizin II152